This inventor holds 5 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Novartis Ag. Active years: 2018-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Zurich, CH (2018 - 2020)
- Basel, CH (2019 - 2022)
Company Filing History:
Years Active: 2018-2022
Title: Florian Karl Kleinbeck-Riniker: Innovating the Field of Chemical Synthesis
Introduction:
Florian Karl Kleinbeck-Riniker is a renowned inventor based in Zurich, Switzerland, with a remarkable contribution to the field of chemical synthesis. With a total of 5 patents under his name, Kleinbeck-Riniker has been instrumental in developing novel processes, intermediates, and catalysts, particularly in the realm of neprilysin (NEP) inhibitors.
Latest Patents:
His latest patents showcase his innovative approach to chemical synthesis for NEP inhibitors. One of his inventions revolves around a new chemical synthesis, intermediates, and catalysts essential for producing the NEP inhibitor sacubitril. This groundbreaking work introduces new intermediate compounds and highlights their significance in the chemical synthesis route. Additionally, Kleinbeck-Riniker's patent focuses on processes and intermediates for NEP inhibitor synthesis, emphasizing the role of nitro compounds and a novel catalyst ligand in the production of sacubitril.
Career Highlights:
Florian Karl Kleinbeck-Riniker is affiliated with Novartis AG, a leading pharmaceutical company known for its dedication to scientific excellence and innovation. Within Novartis AG, Kleinbeck-Riniker has made substantial contributions to advancing the field of chemical synthesis, particularly in developing novel drug compounds and pharmaceutical intermediates.
Collaborations:
Throughout his career, Kleinbeck-Riniker has collaborated closely with esteemed colleagues such as Benjamin Martin and Gerhard Penn. These collaborations have been instrumental in driving forward innovative research initiatives and pushing the boundaries of chemical synthesis within the pharmaceutical industry.
Conclusion:
In conclusion, Florian Karl Kleinbeck-Riniker stands out as a visionary inventor in the realm of chemical synthesis, with a strong focus on NEP inhibitors and pharmaceutical intermediates. His patents reflect a deep commitment to innovation and a relentless pursuit of excellence in developing novel processes and compounds that have the potential to revolutionize the field. Collaborating with top-tier professionals and working within the esteemed Novartis AG, Kleinbeck-Riniker continues to shape the landscape of chemical synthesis and pharmaceutical innovation with his groundbreaking contributions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile